Imeik Technology Development Co., Ltd.

Huons Global Bets on China Hutox Exports to Revive Earnings as Korean Toxin Makers Expand Overseas

- Huons Global's first-half operating profit fell 43.6% to 28.7 billion won, weighed down by one-off costs and the absence of U.S. injectable exports, with earnings recovery expected in the second half. - Hutox, a botulinum toxin made by subsidiary Huons BioPharma, won China NMPA approval in January and began local sales in July through partner Imeik, which has a network of about 7,000 clinics. - Sangsangininvestment&Securities projects Hutox China exports to approach 10 billion won this year, with potential to more than double by 2028 if additional production facilities gain NMPA approval. - South Korea's big three toxin makers—Daewoong, Hugel, and Medytox—posted combined Q2 toxin revenue of 225.9 billion won, driven primarily by expanding overseas sales.